Stockscreener 앱 받기
44.32
0.14%
0.06
시간 외 거래:
44.32
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Contrasting argenx (NASDAQ:ARGX) and Apogee Therapeutics (NASDAQ:APGE) - Defense World
APGE Stock Update: Apogee Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Apogee Therapeutics stock maintains buy rating ahead of key trial data - Investing.com Canada
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System - Defense World
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - sharewise
Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Ameriprise Financial Inc. Makes New $259,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
(APGE) Investment Analysis and Advice - news.stocktradersdaily.com
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com
D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
How To Trade (APGE) - news.stocktradersdaily.com
Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com
Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga
Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha
Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus
Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus
Apogee Therapeutics Q1 Loss Widens - marketscreener.com
Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times
Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq
Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World
Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria
Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia
1.45%
0.86%
자본화:
|
볼륨(24시간):